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Abstract The aim of this systematic review is to appraise
existing literature on the effects of treatments for antenatal
depression on the neurodevelopment outcomes of the off-
spring. We conducted a systematic review of the literature to
identify studies on different kinds of treatments for antenatal
depression (antidepressants and alternative therapies) and
their effects on infants’ neurodevelopment. After reading the
title, abstract, or full text and applying exclusion criteria, a
total of 22 papers were selected. Nineteen papers studied the
effects of antidepressant drugs, one on docosahexanoic acid
(DHA) (fish oil capsules) and two on massage therapy; how-
ever, no studies used a randomized controlled design, and in
most studies, the control group comprise healthy women not
exposed to depression. Comparisons between newborns ex-
posed to antidepressants in utero with those not exposed
showed significant differences in a wide range of neurobe-
havioral outcomes, although in many cases, these symptoms
were transient. Two studies found a slight delay in psychomo-
tor development, and one study found a delay in mental
development. Alternative therapies may have some benefits
on neurodevelopmental outcomes. Our review suggests that
antidepressant treatment may be associated with some
neurodevelopmental changes, but we cannot exclude that
some of these effects may be due to depression per se.
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Introduction
Pregnancy is a sensitive period for a woman’s health, both
physical and psychological. It is the time when a new life
forms in her body and many hormonal variations take place
which can affect mood (Ahokas et al. 2005). In the last two
decades, research into the well-being of women around child-
birth has increasingly focused on depression in the antenatal
rather than in the postnatal period. Studies from different
countries have estimated the prevalence of antenatal depres-
sion to range from 6 to 38%. Different studies have found that
compared to non-pregnant women, pregnant women at any
gestational age have an increased chance of suffering from a
mood disorder such as major or minor depression (Dietz et al.
2007; Marchesi et al. 2009; Marcus 2009). Antenatal depres-
sion has often been found to be more frequent than postnatal
depression, in some cases the estimate being twice that of
depression following birth (Field 2011). Moreover, women
suffering from antenatal depression are at high risk of devel-
oping depression in the postnatal period (Leigh and Milgrom
2008; Marino et al. 2012). According to a number of studies,
the highest risk periods for developing a mood disorder are the
first and last trimester of pregnancy (Gavin et al. 2005; Field
2011; Marchesi et al. 2009).
Numerous studies and a recent meta-analysis have shown
that depression throughout pregnancy may lead to complica-
tions (preeclampsia, spontaneous miscarriage) and poor out-
comes for the offspring, such a slow intrauterine growth,
placental abnormalities, low birth weight, preterm birth, and
frequent admission to the neonatal intensive care unit (Bonari
et al. 2004; Deave et al. 2008; Field et al. 2006; Grote et al.
2010). Neonates of depressed mothers perform poorly on
many clusters of the Brazelton Neonatal Behavioral
Assessment Scale (NBAS) such as orientation, reflex, excit-
ability, and withdrawal; they are also more aroused and less
attentive (Hernandez-Reif et al. 2006; Hollins 2007; Lundy
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et al. 1999a). Deave et al. (2008) investigated the long-term
effects of perinatal depression on child development, and they
found that some of the effects on child development previous-
ly believed to be associated with postnatal depression were
instead associated with depressive symptoms during
pregnancy.
Taking these findings into account, it is important to iden-
tify and treat all pregnant women who experience symptoms
of low mood or severe depression in order to reduce adverse
child outcomes. It is not easy for clinicians and mothers to
make decisions about the type of therapy that is appropriate
for each individual pregnant woman.Many factors such as the
severity of the mother’s disease, the consequences of her
illness on the developing fetus, and the long-term outcome
for both mother and baby need to be considered. Guidelines
have been developed to help clinicians decide with their
patients the best form of treatment, giving them adequate
information to give informed consent to the therapy. The
National Institute for Health and Clinical Excellence clinical
guideline underlines that drugs should be prescribed cautious-
ly for womenwho are planning a pregnancy and for those who
are pregnant or breastfeeding. They suggest different therapies
based on the severity of disease: subthreshold, mild, moderate,
severe, and treatment-resistant depression (NICE clinical
guideline 45Antenatal and postnatal mental health Clinical
management and service guidanceIssued: February 2007).
Wisner et al. (2000) introduced five domains: intrauterine fetal
death, physical malformations, growth impairment, behavior-
al teratogenicity, and neonatal toxicity in her decision-making
model to ensure that patients and psychiatrists deal with all the
critical risk-benefit aspects. Koren et al. (Koren and Nordeng
2012) in his recent review also emphasized that very little has
been done to integrate the potential risks, if they exist, and to
allow an evidence-based benefit-risk ratio. Good algorithms to
evaluate and manage the risk of exposure to depression or
antidepressant were made by the American Psychiatric
Association in collaboration with the American College of
Obstetricians and Gynecologists (Yonkers et al. 2009).
Despite these documents helping clinicians and patients
make appropriate decisions, pregnant women were found to
be diffident toward taking antidepressant drugs, with a high
percentage of women discontinuing their use, compared to the
use of other therapies such as the counseling service provided
by the Motherisk Program (Bonari et al. 2005). This reluc-
tance by pregnant women to take antidepressant drugs should
lead clinicians to discuss with their patients the use of psy-
chological interventions or alternative forms of treatments
such as light therapy, massage therapy, or omega-3 fatty acid
supplementation (Dennis et al. 2007; Dennis and Allen 2010).
Currently, the most studied category of treatments is antide-
pressant use and its effects on the mothers and babies. There is
some evidence to show that therapies other than drugs are
effective forms of treatment for the mother’s mental illness,
but to our knowledge, there are no recent systematic reports on
the their impact of antidepressant treatment on the newborn
focusing on neurodevelopment (Chaudron 2013; Gentile and
Galbally 2011; Lattimore et al. 2005), rather than poor neo-
natal adaptation syndrome or similar reaction at births
(Grigoriadis et al. 2013). The aim of this study is to review
existing literature on the neurodevelopmental outcome of
newborns born to mothers who were treated for antenatal
depression with drugs or alternative therapies. Alternative
therapies could have a number of beneficial effects on the
offspring through direct nutritional effects or by improving
symptoms and well-being in the mothers, but, especially
considering their widespread use, it is important to identify
any potential negative consequences.
Materials and methods
The words “antenatal or postnatal or antepartum or postpar-
tum or peripartum or prepartum or perinatal or pregnancy or
neonatal” and “depression” and “treatment or NBAS or
Bayley or neurodevelopment or baby outcome”were searched
from 1950 to May 2013 in the PubMed, The Cochrane
Library, Scopus, Embase, OvidSP, PsychInfo, and ISI Web
of Knowledge. The resultant papers were cross-referenced for
other relevant studies not identified in the initial research. An
extensive manual research of literature was also done by
checking pertinent journal and authors. The only studies se-
lected were ones that assessed pregnant women with depres-
sion who were treated with drugs or alternative therapies, and
where their newborns were measured specifically by using
standardized tests of neurodevelopmental outcomes adminis-
tered by trained staff. Other papers where symptoms are
described based on questionnaire or clinical notes were not
included. The tests used for neurobehavioral assessment of the
infant were NBAS (Brazelton 1973) and NICU Network
Neurobehavioral Scale (NNNS) (Lester and Tronick 2004).
The same methodology was used for the selection of studies
that assessed neurodevelopment and long-term effects on
infants. The tests used were the Bayley Scales of Infant
Development (BSID) second and third editions (Bayley
1993, 2005), the Wechsler Preschool and Primary Scale of
Intelligence third edition (WPPSI) (Wechsler 2002), the
Wechsler Adult Intelligence Scale (Wechsler 1981, 1999),
the BOEL test (Junker et al. 1982), the McCarthy Scale
(McCarthy 1972), and the Reynell Developmental Language
Scale (Reynell 1985).
Including clinical trial, meta-analysis, randomized con-
trolled trial, review, and systematic reviews, we found 2,332
papers in 8 search engines. We excluded papers not written in
English or based on animal models, and after reading the title,
abstract, or full article, only 22 studies met inclusion criteria
(Table 1).
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The majority of the literature focused on the birth outcomes
(birth weight, length of gestation, Apgar score) for the infants
following treatment of the mother’s depression. To our knowl-
edge, there are only a very few studies that examined short-
and long-term neurodevelopmental outcomes for the baby.
This is true especially for therapies other than drugs. In 19
papers out of the 22 selected, mothers were treated with
selective serotonin reuptake inhibitors (SSRI) as citalopram,
fluoxetine, sertraline, paroxetine, fluvoxamine, and
escitalopram, or serotonin–norepinephrine reuptake inhibitor
(SNRI) as venlafaxine.We found only one paper that analyzed
the effects of docosahexanoic acid (DHA)-rich fish oil cap-
sules and two papers that explored massage therapy. Only the
studies on alternative therapies were randomized controlled
trials with a placebo group of depressed mothers. All the other
studies were prospective cohort studies.
Results
The selected papers were arranged in ascending order accord-
ing to the age of the babies at the time of assessment, from
birth until 86 months old. The following sections evaluate
short-term effects (from birth to 8 weeks) (Table 2) and long-
term effects (from 2 to 86 months) (Table 3) on offspring




The five studies that met inclusion criteria found significant
differences in the neurobehavioral scores on both the NBAS
and NNNS of newborns exposed to drugs, those exposed to
untreated maternal depression, and newborns of healthy wom-
en (Smith et al. 2013; Salisbury et al. 2011; Rampono et al.
2009, Ferreira et al. 2007; Zeskind and Stephens 2004); only
one study did not find any significant differences (Suri et al.
2011). The most common finding was that infants exposed to
drugs displayed more tremors, agitation, irritability, spasms,
and hyper or hypotonia than infants of healthy women. Some
of these symptoms have been referred to as “neonatal adapta-
tion syndrome” (Grigoriadis et al. 2013), although the studies
described here tend to present a wider range of motor and
behavioral symptoms, and all studies have used standardized
tests of neurodevelopmental outcomes administered by
trained staff, as opposed to questionnaire or clinical notes.
In a recent study, Smith et al. (2013) compared neurobe-
havioral outcomes between neonates who were born to
euthymic women who either took or did not take an SSRI
during the last trimester of pregnancy. The study found sig-
nificant differences on motor cluster scores on the NBAS.
Exposed infants had lower scores than unexposed, specifically
on the pull-to-sit item on the motor cluster, which measures
traction, head control, and neck muscle strength. The signifi-
cant differences on motor cluster became marginal (p=0.05)
after adjustment for gestational age. No other significant dif-
ferences were found regarding infants sleep state and motor
activity. Since other studies have documented that exposure to
maternal depression during the third trimester could affect the
newborn, only women who were euthymic during the third
trimester were used as the comparison group (Hernandez-Reif
et al. 2006; Hollins 2007; Lundy et al. 1999b). However the
study of Smith et al. (2013) was very limited due to the
number (five) of exposed infants assessed.
Salisbury et al. (2011) found lower scores on quality of
movement, such as hypertonic reflexes, startles, tremors,
back-arching, and a greater number of the central nervous
system stress signs, in infants exposed to SSRI compared with
those exposed to untreated depression or to infants of healthy
women. These differences were not related to depression
severity or timing or length of SSRI exposure. Newborns
exposed to depression had the highest quality of movement
scores but significantly lower scores on attention items com-
pared to the other two groups. These findings are similar to
other studies cited above, even though they used a more recent
test, the NNNS test, developed by Lester and Tronick (2004).
The NNNS test assesses the following: neurological func-
tions, as active and passive tone, reflexes and central nervous
system integrity; behavioral items including state, sensory,
and interactive response; stress and abstinence items. In the
other three selected studies, different antidepressants that
work on reuptake of norepinephrine or dopamine, such as
venlafaxine and bupropion, were used, in addition to SSRI.
Main effects were found on the motor and autonomic clusters
of the NBAS, which were similar to other studies cited above
(Rampono et al. 2009; Ferreira et al. 2007; Zeskind and
Stephens 2004).
Suri et al. (2011) reported no significant differences be-
tween newborns of mothers with a history of major depressive
disorder, those exposed to antidepressants in utero, and a
Table 1 Studies that met the inclusion criteria
Search engine Papers New selected papers
PubMed 546 17





ISI Web of Knowledge 218 0
Added from references 4 4
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control group born to healthy mothers. The newborns exposed
to antidepressant had significantly lower scores on the rapidity
of buildup item under the range of state cluster and on
the response to inanimate auditory stimulation item un-
der the orientation cluster and higher score on the
defensive scale under the motor cluster when compared
to the other two groups. The differences were however
small and could be due to some of the limitations of the
study: the numbers in each group were small, the
grouping of multiple antidepressants did not allow for
the differentiation of the effects of each single drug, and
the use of different settings at home or in hospital for
the NBAS assessment.
Alternative therapies
Only two studies on alternative therapies for maternal
depression and the short-term effects on infant
neurodevelopmental outcomes met our inclusion criteria.
Field et al. widely studied the effects of depression on the
health of women and babies during pregnancy and the
benefits of massage therapy for pregnant women (Field
2011; Field et al. 2006; Field et al. 1999). In two ran-
domized clinical trials (Field et al. 2004, 2009), they
assessed the effects of massage therapy. The NBAS was
used to examine the neurobehavioral development of in-
fants in both studies. The massage therapy was carried out
over two sessions of 20 min per week during the second
and third trimester of pregnancy. The massage was per-
formed by “significant others” of the women who were
then trained by massage therapists.
In the 2004 study, newborns born to mothers in the mas-
sage therapy group had better performance on the NBAS with
significant better scores than the control group on the habitu-
ation, range of state, autonomic stability, withdrawal scales,
depressed scale, and motor maturity scale. In the study con-
ducted in 2009, the newborns of the massage group performed
significantly better on the NBAS on habituation, orientation,
motor, and depression score items. In addition, they had lower
cortisol levels that could be related to the lower cortisol level
of massage therapy mothers. Moreover, after the massage
therapy, the newborns tended to have better neonatal outcome
with fewer incidences of low birth weight and prematurity in
both studies.
Long-term effects
To evaluate the long-term effects of drugs or alternative ther-
apies, babies’ outcomes were divided into three categories:
psychomotor, mental, and cognitive development, according
to the tests used in the selected papers.
Antidepressants
Four studies (Hanley et al. 2013; Casper et al. 2011;
Mortensen et al. 2003; Casper et al. 2003) found significant
negative associations between treatments with antidepressants
and psychomotor development scores on the Bayley scale
(Bayley 1993) and on the Boel test (Junker et al. 1982). In a
recent study, Hanley et al. (2013) studied the effects of expo-
sure to SSRI on 10-month-old babies whose mothers took
antidepressants throughout the pregnancy. They found that
infants who were exposed to drugs in the antenatal period
scored significantly lower on the gross motor, social-emotion-
al, and adaptive behavior items compared with those not
exposed. They also investigated the effects of maternal mood
during pregnancy and postpartum on infants’ development,
and found no significant effects of exposure to antidepressants
in any of Bayley items.
Similar results were found by Mortensen et al. (2003). A
higher percentage of abnormal Boel items, a psychomotor
development test based on 14 items (Junker et al. 1982), were
found among exposed compared those who were not exposed
to antidepressants and other psychiatric drugs. Casper et al.
conducted two studies (2003, 2011) to evaluate the effects of
antenatal exposure to antidepressants on children born to
depressed mothers. In the first study, they found significant
lower scores for the Psychomotor Development Index and
Motor Quality Factor of the Bayley Behavioural Rating
Scale (a subscale of the Bayley that assesses qualitative as-
pects of the child’s behavior during the testing situation) in the
group exposed to antidepressants compared with unexposed
children. In the last study, they also evaluated the effects of the
duration of exposure to SSRI and found a significant negative
correlation between the length of the exposure and the
psychomotor development index, while no significant
correlations were found with the mental development index.
Oberlander et al. (2004) did not found any significant differ-
ences in the Bayley assessment at 2 and 8 months in the
Psychomotor Development Index (PDI) between newborns
exposed or not exposed to antidepressants. They found a
higher incidence of poor neonatal adaptation syndrome at
birth in newborns exposed to SSRI alone or in combination
with benzodiazepine, especially those who were exposed to
the combination of paroxetine and clonazepam. Within the
entire exposed group, 30 % of newborns, compared with 9 %
of control group, showed symptoms of mild respiratory dis-
tress, hypotonia, jittery, tremors and hypertonia, cardiac ar-
rhythmia, bradycardia, and hypoglycemia. After 48 h, symp-
toms had disappeared in all babies. These findings are in
agreement with a recent study by Jordan et al. (2008), and a
review by Moses-Kolko et al. (2005) where poor neonatal
adaption syndrome, including SSRI withdrawal, SSRI toxic-
ity, serotonergic excess, serotonergic CNS adverse effects,
serotonin syndrome, and neonatal behavioral syndrome,
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affects 25–30 % of newborns whose mothers took SSRI
antidepressants during pregnancy, with an overall risk ratio
of 3.0 (95 % CI 2.0–4.4).
None of the selected studies found significant differences
in the Mental Development Index (MDI) of the Bayley scale
or in the General Cognitive Index (GCI) of the McCarthy
scale (Table 2). However significant differences were found
in the Wechsler Preschool and Primary Scale of Intelligence
(Nulman et al. 2012). In this recent study, Nulman et al.
(Nulman et al. 2012) compared the IQ of children exposed
to antidepressants during pregnancy with the IQ of children of
mothers with untreated depression and the children of healthy
mothers. They found that children exposed to venlafaxine or
SSRI had a significantly lower score in the full-scale IQ test, in
the verbal IQ scale, and in the performance IQ scale of the
WPPSI compared to the control group. The IQ of children
whose mothers had untreated depression was similar to those
of children exposed to drugs, but the IQ value was not signif-
icantly lower compared with the control group. Neither the
length of the exposure during the pregnancy nor the dosage of
the drugs had an effect on any cognitive or behavioral out-
come. In her previous studies Nulman et al. (Nulman and
Koren 1996, Nulman et al. 1997, Nulman et al. 2002) had
established that exposure to tricyclic antidepressants and flu-
oxetine do not adversely affect the cognitive, language, and
behavioral development of children, as measured by the MDI
of the Bayley, the McCarthy, and the Reynell scales. The
duration of depression and the number of episodes after de-
livery were negatively associated with IQ and language
development.
Other authors (Galbally et al. 2011; Reebye et al. 2002) did
not find any significant differences in the cognitive and lan-
guage scores, as measured by the Bayley, of children exposed
to antidepressants and those in the control group. Galbally
found a difference on the motor subscale with a moderate
Cohen’s effect size for fine and gross motor. Neither Mattson
et al. (1999) with the WPPSI nor Morison et al. (2001) with
the Bayley found any significant differences between children
exposed to SSRI and control group.
Alternative therapies
Only one study on the therapeutic effects of dietary DHA by
Makrides et al. (2010) met the criteria to be included in the
review. The therapeutic effects of omega-3 during pregnancy
were shown to improve gestational outcomes, and its thera-
peutic use in treating depression has been confirmed by many
authors (Larqué et al. 2012; Su et al. 2008), and interestingly,
this is the only randomized controlled trial of this systematic
review.
Makrides et al. (2010) evaluated the neurodevelopmental
effect of DHA treatment on young children, assessed at
18 months. They did not find any significant differences in
the cognitive, language, motor, social-emotional, and adaptive
behavior standardized scores on the Bayley Scale III Edition
(Bayley 2005), between children exposed to DHA-rich fish oil
capsules and vegetable oil capsules during pregnancy and a
control group of children exposed to placebo. Although in
secondary analyses, they noticed two apparently contrasting
effects: fewer children in the DHA group had delayed cogni-
tive development compared with the control group, and girls
exposed to higher-dose DHA in utero had lower language
scores and were more likely to have delayed language devel-
opment than girls from the control group. In terms of maternal
depression, the DHA capsules were not better than control
treatment to treat or prevent postpartum depression. The main
significant effects found in this study were a decrease in
preterm birth (<34-week gestation) and low birth weight in
the DHA group compared with the control group.
Discussion
This review summarizes the current literature on the
neurodevelopmental outcome of childrenwhosemothers were
treated for antenatal depression with antidepressants or alter-
native therapies. Up until now, the majority of the literature
only studied the effects of antidepressants; only a few studies
have investigated the effects of alternative therapies on in-
fants. The evidence suggests that antidepressants lead to short-
term adverse effects on newborns compared with a control
group. The motor and autonomic systems are most affected.
Studies show that babies who are exposed to drugs present
with more tremors, agitation, irritability, spasms, and hyper-
tonia or hypotonia. Many symptoms are however transient
and mild (Jordan et al. 2008; Moses-Kolko et al. 2005). The
symptoms found in the newborns could be due to toxicity of
the SSRI drugs or to the withdrawal syndrome; a single
explanation has still not been found. However, none of these
studies were randomized controlled trials, and therefore, de-
pression per se may account for at least some of the effects
attributed to antidepressants.
In the long-term, some studies have shown a significant
effect of antidepressants on psychomotor development, with
delay on motor development on the Bayley and Boel assess-
ments. However, other authors have found no significant dif-
ference between those who are exposed and the control group.
No differences have been found for mental development of the
infant: only Nulman et al. (2012) found significantly lower IQ
in children exposed to drugs compared with the control group,
on the WPPSI. However, the values were similar in children
whose mothers were depressed and treated when compared
with children whose mothers were depressed but untreated.
They also evaluated the effects of the length of exposure and
dosage of the drugs and did not find any significant difference.
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Moreover, the duration of depression and the number of epi-
sodes after delivery were negatively associated with IQ and
language development, respectively. Again, this suggests that at
least some of the neurodevelopmental differences identified in
this kind of studies are due, at least in part, to depression per se.
Indeed, there is strong evidence that depression per se can
adversely affect the neurodevelopment and emotional develop-
ment of the offspring through in utero biological programming
of fetus development and of maternal caregiving behavior
(Glover 2011; Pawlby et al. 2011). The potential rescuing
effects of antidepressants on some of these biological mecha-
nisms, such as hypercortisolemia (and Pariante and Lightman
2008), could explain why antidepressant treatment in our re-
view is associated with only minor developmental abnormali-
ties. Of note in this regard is the fact that for obstetric compli-
cations, more severe forms of depression (for example, diag-
nosed as cases using clinical interview as opposed to symptoms
scale) tend to have more severe complications (Grote et al.
2010). However, the studies described in this report, which
often lack information on diagnostic criteria or symptoms se-
verity, do not allow us to draw any conclusion on the impact of
these factors on neurodevelopmental outcomes, and indeed,
epidemiological studies have shown that even milder form of
depression and anxiety can affect long-term offspring behavior
(Glover 2011).
The alternative therapies analyzed in this review did not
have any negative impact on children in the short- or long-
term and found some positive effects. Massage therapy led to
better NBAS scores than control group, and in the DHA
therapy group, there were fewer children with delay on cog-
nitive development even if therapy was not significant better
than placebo to treat depression. It is important to underline
the absence of studies about alternative therapies that look at
the impact on the newborn. While overall, these studies show
important results with this kind of treatment, the number of
studies is small and more randomized/controlled research is
needed in this field.
Limitations
As mentioned above, it is important to consider factors other
than treatments for maternal depression that could influence
neurodevelopmental outcomes of newborns and children.
First, the current mental state of the mothers was not consid-
ered in all studies. In some cases, mothers only had a history
of depression and were taking medication only as prevention
or maintenance treatment. The adverse effect of maternal
depression on the newborn is well known (Grote et al.
2010). It is important therefore to include the mother’s current
mental state when examining the contribution of treatment in
altering the neurodevelopmental outcome of the babies.
Another limitation is the timing and the length of exposure
to the treatment, especially drugs. Casper et al. (2003, 2011)
was the only study that considered different trimesters of ex-
posure to antidepressants, and he found a negative correlation
between the length of the exposure and the behavioral rating
scale on the Bayley assessment. Finally, it is important again to
stress that only the studies on alternative therapies (massage
therapy and omega-3 fatty acid) were randomized controlled
trials with placebo groups; the other studies were prospective or
retrospective studies.
Conclusions
To our knowledge, this is the first review that has examined
the neurodevelopment outcomes of babies exposed in utero to
antidepressants and to alternative therapies. While the short-
term effects seems to be more consistent, these tend to be mild
and self-limiting; in contrast, the results of studies examining
long-term effects are more varied, and it is virtually impossi-
ble to disentangle the effects of antidepressants from the
effects of depression per se. Finally, our findings suggest that
alternative therapies may be safer options. Future studies are
necessary to test new alternative therapies other than drugs
and to provide controlled data on the effects of medications in
pregnancy on the neurodevelopmental outcomes of children.
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